Delgocitinib Drug Asset Due Diligence Report 2026

This Delgocitinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Delgocitinib can convert its Small molecule drug profile and JAK1 x JAK2 x JAK3 x TYK2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Delgocitinib (query alias: delgocitinib)
Modality / target	Small molecule drug; JAK1 x JAK2 x JAK3 x TYK2; JAK1 inhibitors, JAK2 inhibitors, JAK3 inhibitors
Highest global status	Approved
Originator	Japan Tobacco (Hong Kong) Ltd.
Active developers	Leo Pharma, Inc., LEO Pharma A/S, Japan Tobacco, Inc.

The MCP disease footprint includes Chronic eczema, Chronic hand eczema, Dermatitis, Atopic. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07335588	Phase 3	Recruiting	652	Number of Participants Achieving IGA-LS TS at Week 12
NCT07671157	Phase 2	Not yet recruiting	30	Hairline measurements
NCT07487948	Phase 2	Recruiting	30	Changes in IFNγ in CA scalp in delgocitinib-treated patients

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Delgocitinib cream for adolescents with moderate to severe chronic hand eczema (DELTA TEEN): a multicentre, double-blind, phase 3 randomised controlled trial

Phase 3; n=98; evaluation: Positive. Reported fields: IGA-CHE treatment success(week 16) = 29.0 % ; IGA-CHE treatment success(week 16) = 64.0 %

The DELTA TEEN Phase 3 trial: systemic exposure and safety profile of delgocitinib cream in adolescents with moderate to severe Chronic Hand Eczema

Phase 3; n=98; evaluation: Positive. Reported fields: AE(related) = 8.3 % ; AE(related) = 2.7 %

Delgocitinib cream 20 mg/g for moderate to severe Chronic Hand Eczema: outcomes over 16 weeks by prior systemic therapy exposure

Phase 3; n=1017; evaluation: Positive. Reported fields: HECSI-75 = 75.0 % ; HECSI-75: P-Value = <0.05; P-Value = <0.05; HECSI-75: P-Value = <0.05; P-Value = <0.05

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Delgocitinib addresses Chronic eczema, Chronic hand eczema, Dermatitis, Atopic. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2018-03-15	JT Signs Exclusive License Agreement with ROHTO Pharmaceutical for the Development and Commercialization of JAK Inhibitor in Japan	Discovery	Financial terms not disclosed
2016-10-28	JT and Torii Sign Exclusive License Agreement for Development and \Commercialization of JAK Inhibitor in Japan	Phase 2	Financial terms not disclosed
2014-11-04	LEO Pharma And Japan Tobacco Enter Into License Agreement For Novel JAK inhibitor Drug Candidate	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Crystalline form of delgocitinib”. The milestone feed surfaced a patent-application signal described as “Solid state forms of delgocitinib and process thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO